Latest

GMP requires contemporaneous records, and the executed batch record itself is often complete. What is frequently missing is the decision context around a consequential disposition — the evidence considered, the alternatives assessed, the risk judgment, and the authorization. Rebuilding that context after the fact is the Reconstruction Tax: for planning purposes, a consequential batch disposition can reasonably involve five to eight contributors, 60–150 hours of combined retrospective work, and two to six weeks of elapsed time.

Quality systems reliably preserve what was decided—the disposition, signature, and closure. They do not always preserve why that decision was authorized. FDA enforcement records show what happens when organizations must revisit historical investigations and reconstruct the evidence, context, and reasoning behind prior decisions.

Every GMP organization can prove what it decided. Fewer can still explain why — and reconstructing that reasoning after the fact is a recurring, unbudgeted operating expense, not a documentation gap. This analysis traces the six-stage reconstruction cycle that repeats across deviations, CAPAs, batch releases, and change control, and what it costs to keep paying for the same reasoning twice.

Traci Waldecker turns the inspection lens on hiring. When a process starts optimizing for its proxies instead of its purpose, it can run perfectly and still stop finding the people it was built to find.

The batch record proves the process executed as designed. It does not record how the decision to release a borderline lot was made — the standard a qualified reviewer applies when evidence is ambiguous. Until that reasoning is externalized at the moment of disposition, the organization's true disposition standard stays uncontrolled, non-transferable, and vulnerable to drift.

Most batch records prove every step was performed. Investigators reconstruct why a lot carrying a recorded deviation was authorized for release — on what evidence, against which standard, at what moment. The 483 cites the absence of documented release rationale, not bad product.

Most batch records prove every step was performed. Investigators reconstruct why a lot carrying a recorded deviation was authorized for release — on what evidence, against which standard, at what moment. The 483 cites the absence of documented release rationale, not bad product.

An FDA investigator doesn't challenge whether you made the decision. They challenge whether you can still prove it was justified.

On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. When the comment window closes on June 29, the remaining legal pathway for bulk GLP-1s seals — and inspectors will work backward through the authorization logic behind every release, EAC determination, and CFU continuation decision in the prior twelve months.

Part 2 of a two-part series. The first piece examined what happens when AI fragments the reasoning behind GMP decisions. This piece examines what shifts inside the Quality Unit when the bottleneck moves from execution to articulation.

A deviation closes in four minutes. The AI model recommended non-impacting, the reviewer accepted, the file shows the closure and the signature. Eighteen months later, an investigator pulls the record. The reasoning behind the acceptance is gone.

The corrective action was implemented. The effectiveness check was completed. The CAPA was closed. When the inspector asked who authorized the effectiveness determination — the record that should have answered that question did not exist.

Two QPs. Two facilities. The same decision made the same way — and only one of them survived the inspection.

The investigation was complete. The root cause was documented. The CAPA was opened. When the inspector asked who authorized the root cause conclusion — the record that should have answered that question did not exist.